A critique of the second consensus criteria for multiple system atrophyIva Stanković, Niall Quinn, Luca Vignatelli et al.|Movement Disorders|2019Cited by 92
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialPepijn Eijsvogel, Jean‐Cosme Dodart, Pinaki Misra et al.|Nature Medicine|2024Cited by 38
Precise disease heterogeneity and progression quantification in MSA and Parkinson’s disease using machine learningRobel K Gebre, Prashanthi Vemuri, P. A. Low et al.|Scientific Reports|2026Cited by 0